Referencias
1. Ministerio de Salud y Protección Social. Guía de práctica clínica para la prevención, detección, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años [internet]. 2014. Disponible en: http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_563/GPC_dislipidemias/gpc_dislipidemias.aspx
2. Yusuf S, Hawken S, Ounpuu S, et al. Investigators IS. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. DOI: 10.1016/S0140-6736(04)17018-9
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the multiple risk factor intervention trial (mrfit). JAMA. 1986;256(20):2823-2828. doi:10.1001/jama.1986.03380200061022
4. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease overall findings and differences by age for 316099 white men. Arch Intern Med. 1992;152(1):56-64. doi:10.1001/archinte.1992.00400130082009
5. Wallis EJ, Ramsay LE, Haq IU, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ. 2000;320(7236):671-676. https://doi.org/10.1136/bmj.320.7236.671
6. Ballantyne CM, Grundy SM, Oberman A, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab. 2000;85(6):2089-2112. doi: 10.1210/jcem.85.6.6642-1
7. Flather M. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. DOI: 10.1016/S0140-6736(10)61350-5
8. Soran H, Adam S, Mohammad JB, et al. Hypercholesterolaemia: practical information for non-specialists. Arch Med Sci. 2018;14(1):1. doi: 10.5114/aoms.2018.72238
9. Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020;8(1):36-49. https://doi.org/10.1016/S2213-8587(19)30388-2
10. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780
11. Carr SS, Hooper AJ, Sullivan DR, et al. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019;51(2):148-154. https://doi.org/10.1016/j.pathol.2018.11.006
12. Da Silva PM, Duarte JS, Von Hafe P, et al. Standardization of laboratory and lipid profile evaluation: a call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines. Full report. Atheroscler Suppl. 2018;31:e1-e12. https://doi.org/10.1016/j.atherosclerosissup.2018.04.001
13. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(s2):1-87. https://doi.org/10.4158/EP171764.APPGL
14. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455
15. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. https://doi.org/10.1093/eurheartj/ehw272
16. Mytilinaiou M, Kyrou I, Khan M, et al. Familial hypercholesterolemia: new horizons for diagnosis and effective management. Front Pharmacol. 2018;9(707):1-29. https://doi.org/10.3389/fphar.2018.00707
17. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847. https://doi.org/10.1161/01.CIR.97.18.1837
18. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019;73(24):3153-3167. DOI: 10.1016/j.jacc.2018.11.005
19. Munoz, OM, Rodríguez NI, Ruiz A, et al. Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana. Rev Esp Cardiol. 2014;21(4):202-212. https://doi.org/10.1016/j.rccar.2014.02.001
20. Hajifathalian K, Ueda P, Lu Y, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015;3(5):339-355. https://doi.org/10.1016/S2213-8587(15)00081-9
21. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-3209. DOI: 10.1016/j.jacc.2018.11.002
22. Domanski MJ, Fuster V, Diaz-Mitoma F, et al. Next steps in primary prevention of coronary heart disease: rationale for and design of the ECAD trial. J Am Coll Cardiol. 2015;66(16):1828-1836. DOI: 10.1016/j.jacc.2015.08.857
23. Ference BA, Graham I, Tokgozoglu L, et al. Reprint of: Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(23 Part B):2980-2995. DOI: 10.1016/j.jacc.2018.10.021
24. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. https://doi.org/10.1093/eurheartj/ehw106
25. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. DOI: 10.1056/NEJMoa1800389
26. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275(2):128-133. doi:10.1001/jama.1996.03530260042029
27. Hunninghake DB, Stein EA, Bays HE, et al. Rosuvastatin improves the atherogenic and atheroprotective